Fungaemia in haematological malignancies: SEIFEM-2015 survey.


Journal

European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331

Informations de publication

Date de publication:
May 2019
Historique:
received: 28 08 2018
revised: 29 01 2019
accepted: 04 02 2019
pubmed: 9 2 2019
medline: 18 12 2019
entrez: 9 2 2019
Statut: ppublish

Résumé

Fungal infections are still a relevant challenge for clinicians involved in the cure of patients with cancer. We retrospectively reviewed charts of hospitalized patients with haematological malignancies (HMs), in which a documented fungaemia was diagnosed between January 2011 and December 2015 at 28 adult and 6 paediatric Italian Hematology Departments. During the study period, we recorded 215 fungal bloodstream infections (BSI). Microbiological analyses documented that BSI was due to moulds in 17 patients (8%) and yeasts in 198 patients (92%), being Candida spp identified in 174 patients (81%). Mortality rates were 70% and 39% for mould and yeast infections, respectively. Infection was the main cause of death in 53% of the mould and 18% of the yeast groups. At the multivariate analysis, ECOG ≥ 2 and septic shock were significantly associated with increased mortality, and removal of central venous catheter (CVC) survival was found to be protective. When considering patients with candidemia only, ECOG ≥ 2 and removal of CVC were statistically associated with overall mortality. Although candidemia represents a group of BSI with a good prognosis, its risk factors largely overlap with those identified for all fungaemias, even though the candidemia-related mortality is lower when compared to other fungal BSI. Management of fungal BSI is still a complex issue, in which both patients and disease characteristics should be focused to address a personalized approach.

Sections du résumé

BACKGROUND BACKGROUND
Fungal infections are still a relevant challenge for clinicians involved in the cure of patients with cancer. We retrospectively reviewed charts of hospitalized patients with haematological malignancies (HMs), in which a documented fungaemia was diagnosed between January 2011 and December 2015 at 28 adult and 6 paediatric Italian Hematology Departments.
METHODS METHODS
During the study period, we recorded 215 fungal bloodstream infections (BSI). Microbiological analyses documented that BSI was due to moulds in 17 patients (8%) and yeasts in 198 patients (92%), being Candida spp identified in 174 patients (81%).
RESULTS RESULTS
Mortality rates were 70% and 39% for mould and yeast infections, respectively. Infection was the main cause of death in 53% of the mould and 18% of the yeast groups. At the multivariate analysis, ECOG ≥ 2 and septic shock were significantly associated with increased mortality, and removal of central venous catheter (CVC) survival was found to be protective. When considering patients with candidemia only, ECOG ≥ 2 and removal of CVC were statistically associated with overall mortality.
CONCLUSIONS CONCLUSIONS
Although candidemia represents a group of BSI with a good prognosis, its risk factors largely overlap with those identified for all fungaemias, even though the candidemia-related mortality is lower when compared to other fungal BSI. Management of fungal BSI is still a complex issue, in which both patients and disease characteristics should be focused to address a personalized approach.

Identifiants

pubmed: 30735240
doi: 10.1111/eci.13083
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13083

Investigateurs

Giulia Dragonetti (G)
Stelvio Ballanti (S)
Mario Delia (M)
Gianpaolo Nadali (G)
Sciumè M (S)
Castagnola C (C)
Ferrari A (F)
Mancini V (M)
Decembrino N (D)
Spolzino A (S)
Iovino L (I)
Martino B (M)
Vacca A (V)
Calore E (C)
Fanci R (F)
Lessi F (L)
Vallero S (V)
Zama D (Z)
Cesaro S (C)
De Paolis Mr (P)
Facchini L (F)
Muggeo P (M)
Offidani M (O)
Perruccio K (P)
Russo D (R)

Informations de copyright

© 2019 Stichting European Society for Clinical Investigation Journal Foundation.

Auteurs

Marianna Criscuolo (M)

Dipartimento Scienze Radiologiche Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Francesco Marchesi (F)

Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Anna Candoni (A)

Clinica Ematologica, Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.

Chiara Cattaneo (C)

Hematology, Spedali Civili, Brescia, Italy.

Annamaria Nosari (A)

Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.

Barbara Veggia (B)

Department of Hematology, Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy.

Luisa Verga (L)

Ematologia adulti e CTA ASST Monza, Università Milano Bicocca, Ospedale San Gerardo, Monza, Italy.

Nicola Fracchiolla (N)

Hematology, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano, Italy.

Nicola Vianelli (N)

Department of Onco-Hematology, Policlinico S. Orsola - Malpighi Università di Bologna, Bologna, Italy.

Maria Ilaria Del Principe (MI)

Hematology, University of Rome "Tor Vergata", Rome, Italy.

Marco Picardi (M)

Department of Advanced Biomedical Science, AOU-Federico II Napoli, Napoli, Italy.

Mario Tumbarello (M)

Department of Infectious Diseases, Fondazione Policlinico A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy.

Franco Aversa (F)

Hematology, University of Parma, Parma, Italy.

Alessandro Busca (A)

Department of Hematology, Ospedale Le Molinette Torino, Torino, Italy.

Livio Pagano (L)

Dipartimento Scienze Radiologiche Radioterapiche ed Ematologiche, Fondazione Policlinico A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH